Strategic consulting and PK/PD modelling services dedicated to preclinical and clinical biotherapeutics development

 
 

Mission

We support the translation of innovation into pharmacological concepts and therapies. We believe that the most innovative therapeutic ideas deserve the best development tools. We use Systems Pharmacology as a key tool to maximize the success of your preclinical program, clinical study or registration.

Services

Our services includes consultancy and implementation of systems pharmacology and PK/PD modelling for target assessment, format selection, compound design, candidate selection, design and analysis of preclinical PK/PD and GLP toxicology studies, first in human dose selection, paediatric dose selection  and dose / regimen finding studies.

Why choose us

Our methods have been successfully applied in global pharmaceutical companies with tangible results including patents. We have the unique tested expertise developing bi-specifics, antibody-drug conjugates, scFv’s, nanobodies, cell based therapies to provide tailored support for your program.

Partners

label_web_iBxN_withBGLYO-X is member of the iBx Network. We provide integrated consulting in toxicology, pathology, preclinical and clinical pharmacology and regulatory strategies.

lixoft_labelLYO-X is partnering with Lixoft to provide you access to Monolix the scientifically and technologically most advanced software for preclinical and clinical data analysis.

 

Learn more why Systems Pharmacology is a critical tool for the development of novel Biologics

  • Postdoctoral position

    Automated skin lesion detection and severity classification using image analysis and machine learning. Unique opportunity to boost your career in Switzerland as an outstanding researcher. Application deadline: July 15. 2018. See our career website for more details.

  • Poster presentation at PAGE 2018

    Systems Pharmacology model of peripheral serotonin production proposing two different synthesis compartments with markedly different release rates into blood. Link to abstract M. Machacek (1), L. Renaud (1), C. Kohl (2), M. Vercauteren (2), L. Remen (2), R. Welford (2). (1) LYO-X GmbH, Ringstrasse 9, 4123 Allschwil, Switzerland. (2) Idorsia Pharmaceuticals … Read More

  • 12th Basel M&S Seminar: ‘Modelling … AND SIMULATION’

    We will present at the 12th Basel M&S Seminar Sept 20, 2016 on ‘Modelling … AND SIMULATION’. Yes, although its is called M&S the reality is quite different with a historically large emphasis on modelling. We will discuss the relevance of simulations and their key importance and provide a showcase … Read More